ChemAbout
© 2026 ChemAbout
İçgörüler|Gizlilik Politikası|Kullanım Koşulları|[email protected]
Ana Sayfa/Bileşikler/Aktif Farmasötik İngredient/Insulin glargine
C267H404N72O78S6
6063 g/mol
Aktif Farmasötik İngredientUyarı

Insulin glargine

CAS160337-95-1
Kategori
Aktif Farmasötik İngredient
Bileşik Sınıfı
Peptit
Birincil Kullanım
Farmasötik ham madde

Insulin glargine is a long-acting insulin analog used as a pharmaceutical raw material in the manufacturing of insulin products. It is a large, flexible polypeptide with a complex structure characterized by multiple disulfide bridges and extensive hydrogen-bonding capacity.

pharmaceutical raw material for insulin analog formulations

İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.

Bu bileşiği tedarik ediyor veya sağlıyor musunuz?

Envanterinizi listeleyin veya satın alma talebi gönderin

CAS 160337-95-1

Bu Ürünü Listele
Tedarik bilgisi yayınlamak için oturum açın
Bu Ürünü Talep Et
Kayıt olmadan talep gönderin

İlgili Bileşikler

GüçlüBenzer yapıBenzerlik 0.96

Insulin human

CAS11061-68-0

active pharmaceutical ingredient

GüçlüBenzer yapıBenzerlik 0.93

İnsülin - Degludec

CAS844439-96-9

active pharmaceutical ingredient

GüçlüBenzer yapıBenzerlik 0.93

Insulin detemir

CAS169148-63-4

active pharmaceutical ingredient

GüçlüBenzer yapıBenzerlik 0.85

Insulin, neutral

CAS12584-58-6

active pharmaceutical ingredient

ReferansAynı kategori

3-((2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)oxy)-4-(trimethylazaniumyl)butanoate

CAS160468-17-7

active pharmaceutical ingredient

ReferansAynı kategori

ISOSORBIDE MONONITRATE

CAS16051-77-7

active pharmaceutical ingredient

ReferansAynı kategori

Gatifloxacin hydrochloride

CAS160738-57-8

active pharmaceutical ingredient

ReferansAynı kategori

Faricimabum

CAS1607793-29-2

active pharmaceutical ingredient

Güvenlik Referansı

Sağlık Tehlikesi
Sağlık Tehlikesi
Uyarı
H373May cause damage to organs through prolonged or repeated exposure
Tanımlayıcılar
IUPAC Adı

(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid

InChIKey

COCFEDIXXNGUNL-RFKWWTKHSA-N

SMILES

CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN

Eş Anlamlılar (54)
  • 901, HOE
  • Abasaglar
  • Abasaglar kwikpen
  • BASAGLAR KwikPen
  • BASAGLAR Tempo Pen
  • Basaglar
  • Glargin
  • Glargine
  • Glargine, Insulin
  • Glargine-aglr, Insulin
  • HOE 71GT
  • Ins lantus
  • Ins lantus opticlik
  • Ins lantus optiset
  • Ins lantus solostar
  • Insulin 1556
  • Insulin Glargine (>90%)
  • Insulin Glargine Solostar
  • Insulin Glargine recombinant
  • Insulin glargine
  • Insulin glargine CRS
  • Insulin glargine U-300
  • Insulin glargine U-300 Max
  • Insulin glargine-yfgn
  • Insulina glargina
  • Lantus
  • Lantus R
  • Lantus Solostar
  • Lusduna
  • Lusduna Nexvue
  • Optisulin
  • REZVOGLAR KWIKPEN
  • Rezvoglar
  • Semglee
  • SoloStar
  • Solostar, Lantus
  • TOUJEO MAX SOLOSTAR
  • TOUJEO Max
  • Toujeo
  • Toujeo Solostar
  • insulin glargin
  • insuline glargine
  • insulinum glarginum